27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
The FDA has issued a complete response letter (CRL) for Athenex Inc’s (NASDAQ: ATNX) marketing application seeking approval for oral paclitaxel plus encequidar to treat metastatic breast cancer.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
- The CRL indicated concern about an increase in neutropenia-related sequelae observed on the oral paclitaxel arm compared with the IV paclitaxel arm.
- The FDA also expressed concerns regarding the uncertainty over the results of the primary endpoint of objective response rate at week 19 conducted by blinded independent central review (BICR).
- It suggested that the BICR was influenced.
- The agency recommended that the company conduct a new trial and adopt additional risk mitigation strategies to improve toxicity.
- Athenex plans to request a meeting with the FDA to discuss the agency’s response.
- Price Action: ATNX shares dropped 21% at $9.49 in the premarket before the trading halted. It will resume at 7:35 a.m. ET.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.